Capsant Neurotechnologies Ltd




University of Southampton

Company Stage:


Capsant Neurotechnologies Ltd

Capsant Neurotechnologies is focused on solving problems in the discovery of novel targets and drugs for central nervous system disorders such as stroke, trauma, epilepsy, Parkinson's and Alzheimer's.

The company has a technology platform based on organotypic slice cultures. Capsant's organotypic slices have characteristics similar to the brain in vivo. As a result, the slices can be used to observe normal brain behaviour. They can also be given the characteristics of diseased brains, and this breakthrough has meant that Capsant can use the slices as screens for new drug candidates.

As at 31 December 2015
IP Group holding 49.9%

Holding represents undiluted beneficial equity interest excluding debt